Abstract:Unlike normal cells, cancer cells frequently exhibit supernumerary centrosomes, leading to formation of multipolar spindles that can trigger cell death. Nevertheless, cancer cells with supernumerary centrosomes escape the deadly consequences of unequal segregation of genomic material by coalescing their centrosomes into two poles. This unique trait of cancer cells presents a promising target for cancer therapy, focusing on selectively attacking cells with supernumerary centrosomes. Nek2A is a kinase involved in mitotic regulation, including the centrosome cycle, where it phosphorylates linker proteins to separate centrosomes. In this study, we investigated if Nek2A also prevents clustering of supernumerary centrosomes, akin to its separation function. Reduction of Nek2A activity, achieved through knockout, silencing, or inhibition, promotes centrosome clustering, whereas its overexpression results in inhibition of clustering. Significantly, prevention of centrosome clustering induces cell death, but only in cancer cells with supernumerary centrosomes, both in vitro and in vivo. Notably, none of the known centrosomal (e.g., CNAP1, Rootletin, Gas2L1) or non-centrosomal (e.g., TRF1, HEC1) Nek2A targets were implicated in this machinery. Additionally, Nek2A operated via a pathway distinct from other proteins involved in centrosome clustering mechanisms, like HSET and NuMA. Through TurboID proximity labeling analysis, we identified novel proteins associated with the centrosome or microtubules, expanding the known interaction partners of Nek2A. KIF2C, in particular, emerged as a novel interactor, confirmed through coimmunoprecipitation and localization analysis. The silencing of KIF2C diminished the impact of Nek2A on centrosome clustering and rescued cell viability. Additionally, elevated Nek2A levels were indicative of better patient outcomes, specifically in those predicted to have excess centrosomes. Therefore, while Nek2A is a proposed target, its use must be specifically adapted to the broader cellular context, especially considering centrosome amplification. Discovering partners such as KIF2C offers fresh insights into cancer biology and new possibilities for targeted treatment.

Targeting NEK2 as a promising therapeutic approach for cancer treatment

Role of NEK2 in tumorigenesis and tumor progression

One Shoot, Three Birds: Targeting NEK2 Orchestrates Chemoradiotherapy, Targeted Therapy, and Immunotherapy in Cancer Treatment.

Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects

Preclinical Activity of MBM-5 in Gastrointestinal Cancer by Inhibiting NEK2 Kinase Activity.

Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells

Comprehensive proteomics analysis reveals novel Nek2-regulated pathways and therapeutic targets in cancer

High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma

Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis

Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction

NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes

NEK2 promotes the migration, invasion, proliferation of ESCC and mediates ESCC immunotherapy

The NEK family of serine/threonine kinases as a biomarker for cancer

The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells

Targeting NEK2 Attenuates Glioblastoma Growth and Radioresistance by Destabilizing Histone Methyltransferase EZH2.

Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer

Design, Synthesis, and Structure Activity Relationship (SAR) Studies of Novel Imidazo[1,2-A] Pyridine Derivatives As Nek2 Inhibitors

Overexpression of NIMA-related Kinase 2 is Associated with Progression and Poor Prognosis of Prostate Cancer

NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells